Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
29.36
+2.23 (8.22%)
At close: Dec 5, 2025, 4:00 PM EST
29.11
-0.25 (-0.85%)
After-hours: Dec 5, 2025, 7:56 PM EST
Terns Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Terns Pharmaceuticals stock ranges from a low of $7.44 to a high of $36. The average analyst price target of $25.59 forecasts a -12.84% decrease in the stock price over the next year.
Price Target: $25.59 (-12.84%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Terns Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 3 |
| Buy | 3 | 3 | 3 | 3 | 4 | 6 |
| Hold | 2 | 2 | 2 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 6 | 8 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citizens | Citizens | Buy Maintains $25 → $35 | Buy | Maintains | $25 → $35 | +19.21% | Nov 26, 2025 |
| Barclays | Barclays | Buy Maintains $28 → $36 | Buy | Maintains | $28 → $36 | +22.62% | Nov 25, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $28 → $35 | Strong Buy | Maintains | $28 → $35 | +19.21% | Nov 19, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $22 → $30 | Buy | Maintains | $22 → $30 | +2.18% | Nov 18, 2025 |
| Mizuho | Mizuho | Buy Maintains $32 → $33 | Buy | Maintains | $32 → $33 | +12.40% | Nov 13, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.10
from -1.12
EPS Next Year
-1.34
from -1.10
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.06 | -1.18 | ||||
| Avg | -1.10 | -1.34 | ||||
| Low | -1.11 | -1.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.